Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Gerhard Hamilton"'
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 5, Pp 1027-1038 (2023)
Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) is now a drugable oncogenic driver and the KRAS G12C variant responds clinically to sotorasib and adagrasib that covalently block the cysteine of the active center and inhibit downstream signal
Externí odkaz:
https://doaj.org/article/3974f7c0caac49f9930c0d8b323ee4cc
Autor:
Barbara Rath, Adelina Plangger, Lukas Klameth, Maximilian Hochmair, Ernst Ulsperger, Bram Boeckx, Christoph Neumayer, Gerhard Hamilton
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 2, Pp 355-365 (2023)
Aim: Coagulation is frequently activated in cancer patients and has been correlated with an unfavorable prognosis. To evaluate whether a putative release of tissue factor (TF) by circulating tumor cells (CTCs) represents a target to impair the dissem
Externí odkaz:
https://doaj.org/article/014f9c9cd76c4d5b859eaf2c3c125f92
Autor:
Yosuke Yamada, Djeda Belharazem-Vitacolonnna, Hanibal Bohnenberger, Christel Weiß, Naoko Matsui, Mark Kriegsmann, Katharina Kriegsmann, Peter Sinn, Katja Simon-Keller, Gerhard Hamilton, Thomas Graeter, Gerhard Preissler, German Ott, Sebastian Schölch, Naoki Nakajima, Akihiko Yoshizawa, Hironori Haga, Hiroshi Date, Roman K. Thomas, Iacopo Petrini, Giuseppe Giaccone, Philipp Ströbel, Alexander Marx
Publikováno v:
Cell Death and Disease, Vol 13, Iss 11, Pp 1-11 (2022)
Abstract Tuft cells are chemosensory epithelial cells in the respiratory tract and several other organs. Recent studies revealed tuft cell-like gene expression signatures in some pulmonary adenocarcinomas, squamous cell carcinomas (SQCC), small cell
Externí odkaz:
https://doaj.org/article/aaade6c0d522458ea3d812565b5a42cc
Autor:
Adelina Plangger, Barbara Rath, Sandra Stickler, Maximilian Hochmair, Clemens Lang, Lukas Weigl, Martin Funovics, Gerhard Hamilton
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-13 (2022)
Abstract KRAS is mutated in approximately 25% of cancer patients and first KRAS G12C-specific inhibitors showed promising responses. Pancreatic cancer has the highest frequency of KRAS mutations but the prevailing KRAS G12D mutation is difficult to t
Externí odkaz:
https://doaj.org/article/9ecf439428d74721a0aa4b6ed64f0d5b
Publikováno v:
Translational Oncology, Vol 14, Iss 12, Pp 101230- (2021)
KRAS is mutated in approximately 25% of Non-small Cell Lung Cancer (NSCLC) patients and first specific inhibitors showed promising responses that may be improved by concurrent interference with downstream signaling pathways. Cell lines exhibiting KRA
Externí odkaz:
https://doaj.org/article/e5fc5117060f4de5bca7b4e054651504
Autor:
Lukas Klameth, Barbara Rath, Maximilian Hochmaier, Doris Moser, Marlene Redl, Felicitas Mungenast, Katharina Gelles, Ernst Ulsperger, Robert Zeillinger, Gerhard Hamilton
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Small cell lung cancer (SCLC) represents 15% of lung cancers and is characterized by early dissemination, development of chemoresistance and a poor prognosis. A host of diverse drugs failed invariably and its mechanisms of global chemoresist
Externí odkaz:
https://doaj.org/article/a2cf85fb0b7042ae8e2904ae222c0bb0
Autor:
Gerhard Hamilton
Publikováno v:
Marine Drugs, Vol 12, Iss 3, Pp 1377-1389 (2014)
Fascaplysin, the natural product of a marine sponge, exhibits anticancer activity against a broad range of tumor cells, presumably through interaction with DNA, and/or as a highly selective cyclin-dependent kinase 4 (CDK4) inhibitor. In this study, c
Externí odkaz:
https://doaj.org/article/d2af074aa39942b78c3138340a25c472
Publikováno v:
Molecules, Vol 19, Iss 2, Pp 2077-2088 (2014)
Advanced small cell lung cancer (SCLC) has a dismal prognosis. Modulation of the camptothecin topotecan, approved for second-line therapy, may improve response. Our recent finding of synergistic enhancement of the cytotoxic activity of camptothecin (
Externí odkaz:
https://doaj.org/article/fc1b6a50bdb24b3a9d6dc83efa735d00
Autor:
Eva Obermayr, Christiane Agreiter, Eva Schuster, Hannah Fabikan, Christoph Weinlinger, Katarina Baluchova, Gerhard Hamilton, Maximilian Hochmair, Robert Zeillinger
Publikováno v:
Cells, Vol 8, Iss 8, p 880 (2019)
At initial diagnosis, most patients with small-cell lung cancer (SCLC) present with metastatic disease with a high number of tumor cells (CTCs) circulating in the blood. We analyzed RNA transcripts specific for neuroendocrine and for epithelial cell
Externí odkaz:
https://doaj.org/article/2f590154beca46e496da7a5d02a1c839
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 9, Pp 813-822 (2012)
First-line treatment of small cell lung cancer (SCLC) with combination chemotherapy consisting of cis-diamminedichloroplatinum(II) (cisplatin) and etoposide is frequently followed by early relapses and a dismal prognosis. Survival of a fraction of tu
Externí odkaz:
https://doaj.org/article/2dbb14a244934587802e8fd02a4e7305